Equal chance of either
MTX-463 or placebo

1 infusion every 4 weeks
(up to 6 total)

Key Inclusion criteria

Age 40+ years old

Diagnosed with IPF
within 7 years

Have a FVC of ≥ 45%
predicted

Approximately
164 Participants

Up to 32 week
duration

WISPer

WT0012-20250612-1

Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with IPF

Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to being enrolled in the study. Not all individuals may qualify for this study.